Protalix Biotherapeutics (PLX) Stock Price Down 7.4%
Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) fell 7.4% during trading on Monday . The stock traded as low as $0.61 and last traded at $0.63. 1,202,793 shares changed hands during mid-day trading, an increase of 4% from the average session volume of 1,161,521 shares. The stock had previously closed at $0.68.
Several research firms have recently commented on PLX. Zacks Investment Research raised shares of Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. HC Wainwright set a $5.00 target price on shares of Protalix Biotherapeutics and gave the stock a “buy” rating in a research report on Thursday, January 4th. Finally, BidaskClub cut shares of Protalix Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 2nd.
The company has a market cap of $323.71, a PE ratio of -0.34 and a beta of 1.02.
An institutional investor recently bought a new position in Protalix Biotherapeutics stock. OxFORD Asset Management LLP acquired a new stake in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 687,796 shares of the company’s stock, valued at approximately $576,000. OxFORD Asset Management LLP owned approximately 0.54% of Protalix Biotherapeutics as of its most recent filing with the Securities and Exchange Commission.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2018/02/05/protalix-biotherapeutics-plx-stock-price-down-7-4.html.
About Protalix Biotherapeutics
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.